舌下神经刺激治疗阻塞性睡眠呼吸暂停成功的内型机制
该研究基于STAR试验91例患者基线多导睡眠图数据,分析舌下神经刺激(HGNS)应答者与不完全应答者的病理生理特征差异。结果显示,应答者与更高的觉醒阈值、更强的肌肉补偿及更低的环路增益独立相关。预测应答者的治疗後AHI约为预测非应答者的四分之一。
要点
- HGNS应答与更高觉醒阈值独立相关(OR 6.76,95%CI 2.44-23.3)。
- 更强肌肉补偿与有利应答独立相关(每SD OR 4.22,95%CI 1.70-12.55)。
- 预测应答者治疗AHI显著低于预测非应答者(4.9 vs 20.7 events/h)。
核心结论
- HGNS治疗的有利应答与导致OSA的病理生理特征相关,尤其是更高的觉醒阈值。
- 结合现有标准,具有有利特征的个体可能被优先考虑精准HGNS治疗。
研究设计与样本
- STAR试验的二次分析,注册号NCT01161420。
- 纳入91/126例患者的基线多导睡眠图原始数据。
- 根据Sands等方法计算环路增益、觉醒阈值、塌陷性和肌肉补偿四个特征。
- 采用逻辑回归评估AHI校正后HGNS应答与OSA特征的关联。
主要发现
- HGNS治疗使AHI从30.7(24.9-39.9)降至8.5(4.0-19.5)events/h(P<0.0001)。
- 91例中53例为应答者。
- 校正分析中,有利应答与更高觉醒阈值独立相关(OR 6.76,95%CI 2.44-23.3,P=0.001)。
- 更强补偿与有利应答独立相关(每SD OR 4.22,95%CI 1.70-12.55,P=0.004)。
- 在 milder collapsibility 中,更低环路增益与有利应答相关(交互作用P=0.003)。
关键数值与推荐
- HGNS应答定义为治疗1年时AHI降低>50%且<10 events/h。
- 有利应答独立关联:觉醒阈值OR 6.76(95%CI 2.44-23.3,P=0.001)。
- 有利应答独立关联:肌肉补偿每SD OR 4.22(95%CI 1.70-12.55,P=0.004)。
- 更 mild collapsibility 中更低环路增益与有利应答相关(交互作用P=0.003)。
临床怎么用
- 基线多导睡眠图内型分析可用于识别可能从HGNS治疗中获益更多的OSA患者。
- 觉醒阈值较高、肌肉补偿较强、环路增益较低(在塌陷性较轻时)者可能优先考虑HGNS。
局限性
- 本研究为STAR试验的二次分析。
- 仅91/126例患者的基线多导睡眠图原始数据可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Approximately one-third of patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) therapy are incomplete responders, despite careful patient selection based on baseline characteristics and drug-induced sleep endoscopy.Objectives: Here we use polysomnographic endotyping to assess the pathophysiological mechanisms underlying favorable versus incomplete responses to HGNS therapy.Methods: Baseline polysomnography data of the STAR (Stimulation Therapy for Apnea Reduction) trial were included. Raw baseline polysomnographic data from 91/126 patients were available for analysis. Traits-loop gain, arousal threshold, collapsibility, and muscle compensation-were calculated from the baseline polysomnography data according to Sands and colleagues (AJRCCM 2018, SLEEP 2018). Logistic regression assessed apnea-hypopnea index (AHI)-adjusted associations between HGNS response (>50% reduction in AHI to <10/h at 1 yr) and OSA traits.Measurements and Main Results: Overall, HGNS treatment reduced AHI from 30.7 (24.9-39.9) to 8.5 (4.0-19.5) events/h (P < 0.0001; median [quartiles 1-3]); N = 53/91 were responders. In adjusted analysis, a favorable response to therapy was independently associated with higher arousal threshold (odds ratio [95% confidence interval]: 6.76 [2.44-23.3], P = 0.001), greater compensation (odds ratio: 4.22 [1.70-12.55] per SD, P = 0.004), and lower loop gain (in milder collapsibility, per significant interaction, P = 0.003). The higher arousal threshold was evident in responders before adjusted analysis. Predicted responders had an approximately fourfold lower treatment AHI versus predicted nonresponders (4.9 [2.7-8.5] vs. 20.7 [10.9-29.7], P < 0.0001; median [quartiles 1-3]); differences remained significant after cross-validation.Conclusions: Favorable responses to HGNS therapy are associated with the pathophysiological traits causing OSA, particularly a higher arousal threshold. Along with established criteria, individuals with favorable traits could potentially be prioritized for precision HGNS therapy.This analysis was a secondary analysis of the STAR trial registered with clinicaltrials.gov (NCT01161420).
引用
- Op de Beeck S, Wellman A, Dieltjens M, et al. Endotypic Mechanisms of Successful Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2021. PMID: 32970962. doi:10.1164/rccm.202006-2176OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。